Please login to the form below

Not currently logged in
Email:
Password:

Nimbus looks to Merck for CEO

Donald Nicholson spent 26 years at US pharma giant

merck donald nicholsonNimbus has appointed Merck & Co's Donald Nicholson as the company's new CEO.

Nicholson spent 26 years at Merck holding various strategic leadership and operational roles in diverse therapeutic areas including respiratory inflammation immunology bone endocrine urology infectious diseases and neurosciences.

He began his career in 1988 at the Merck-Frost Centre for Therapeutic Research in Montreal.

In his new role at Nimbus Nicholson will lead a US biotech with a portfolio of programmes in immunology oncology and metabolic diseases targeting mechanisms that have been traditionally difficult or intractable. The company is expected to enter human clinical trials in early 2015.

It is thrilling to join the company at such a watershed moment as the lead programs move toward clinical development,” said Dr Nicholson. “I look forward to working with such a highly respected team of colleagues Board members and investors to deliver the greatest value of the portfolio to patients.”

1st October 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...

Infographics